Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

8

US Previously Marketed

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Penicillin-binding protein 1A

8

Penicillin-binding protein 1

5

Penicillin-binding protein 1B

5

Penicillin-binding protein 2

5

Penicillin-binding protein 3

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

12

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1981

3

1983

4

1985

5

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Lower respiratory tract infections

9

Urinary tract infections

9

Skin and skin structure infections

8

Cystic fibrosis

5

Gonorrhea

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

12

Primary

5

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

5

CNS Non-penetrant

4

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Glaxo

5

Kyoto Pharmaceutical Industries

4

Toyama

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

12

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

12

EPA CompTox

12

FDA UNII

12

PUBCHEM

12

NCI_THESAURUS

10

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER BETA-LACTAM ANTIBACTERIALS

3

BETA-LACTAM ANTIBACTERIALS, PENICILLINS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Third-generation cephalosporins

3

Penicillins with extended spectrum

2

Combinations of penicillins, incl. beta-lactamase inhibitors

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

9

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 12 results

First page disabled
Previous page disabled
1
Next page
Next page

Ceftazidime anhydrous

DZR1ENT301

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 1

Penicillin-binding protein 4

Penicillin-binding protein 1A

Penicillin-binding protein 2

Penicillin-binding protein 1B

Penicillin-binding protein 3

Conditions:

Urinary tract infections

Skin and skin structure infections

Lower respiratory tract infections

Cystic fibrosis

Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-strea...

m, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients.

PIPERACILLIN ANHYDROUS

9I628532GX

Export Data
Search for Structure

Status:

US Approved Rx (2010)

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 2B

Penicillin-binding protein 1A

Conditions:

Intra-abdominal infections

Skin and skin structure infections

Female pelvic infections

Community-acquired pneumonia

Nosocomial pneumonia

Piperacillin is a semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic which exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. Piperacillin sodium salt is used in com...

bination with the β-lactamase inhibitor tazobactam sodium (ZOSYN®) for the treatment of patients with moderate to severe infections caused by susceptible bacteria.

CEFTIZOXIME

C43C467DPE

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1983

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Conditions:

Meningitis caused by Haemophilus influenzae

Urinary tract infections

Lower respiratory tract infections

Pelvic inflammatory disease

Ceftizoxime is a semisynthetic cephalosporin antibiotic, which can be administered intravenously or intramuscularly. It was sold under brand name, cefizox, but was removed from the US Market in 2007. Cefizox was used to treat different infections, ...

such as lower respiratory tract infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenza; urinary tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. Also for treatment of gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae; pelvic inflammatory disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae; meningitis caused by Haemophilus influenza. In addition, some others infections. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae. Infections caused by aerobic gram ¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. The bactericidal action of ceftizoxime results from inhibition of the third and last stage of bacterial cell wall synthesis. Bacterial cell wall autolytic enzymes such as autolysins then mediate cell lysis; it is possible that ceftizoxime interferes with an autolysin inhibitor. Ceftizoxime is highly resistant to a broad spectrum of beta -lactamases (penicillinase and cephalosporinase), including Richmond types II, III, TEM, IV, produced by both aerobic and anaerobic gram - positive and gram - negative organisms and I.

Ceftazidime anhydrous, (E)-

UU1494IX6R

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 1

Penicillin-binding protein 4

Penicillin-binding protein 1A

Penicillin-binding protein 2

Penicillin-binding protein 1B

Penicillin-binding protein 3

Conditions:

Urinary tract infections

Skin and skin structure infections

Lower respiratory tract infections

Cystic fibrosis

Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-strea...

m, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients.

Ceftazidime dihydrochloride

8ORW199D1G

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 1

Penicillin-binding protein 4

Penicillin-binding protein 1A

Penicillin-binding protein 2

Penicillin-binding protein 1B

Penicillin-binding protein 3

Conditions:

Urinary tract infections

Skin and skin structure infections

Lower respiratory tract infections

Cystic fibrosis

Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-strea...

m, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients.

CEFTAZIDIME SODIUM

CMC30V039K

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 1

Penicillin-binding protein 4

Penicillin-binding protein 1A

Penicillin-binding protein 2

Penicillin-binding protein 1B

Penicillin-binding protein 3

Conditions:

Urinary tract infections

Skin and skin structure infections

Lower respiratory tract infections

Cystic fibrosis

Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-strea...

m, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients.

Ceftazidime

9M416Z9QNR

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 1

Penicillin-binding protein 4

Penicillin-binding protein 1A

Penicillin-binding protein 2

Penicillin-binding protein 1B

Penicillin-binding protein 3

Conditions:

Urinary tract infections

Skin and skin structure infections

Lower respiratory tract infections

Cystic fibrosis

Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-strea...

m, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients.

PIPERACILLIN SODIUM

M98T69Q7HP

Export Data
Search for Structure

Status:

US Approved Rx (2010)

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 2B

Penicillin-binding protein 1A

Conditions:

Intra-abdominal infections

Skin and skin structure infections

Female pelvic infections

Community-acquired pneumonia

Nosocomial pneumonia

Piperacillin is a semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic which exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. Piperacillin sodium salt is used in com...

bination with the β-lactamase inhibitor tazobactam sodium (ZOSYN®) for the treatment of patients with moderate to severe infections caused by susceptible bacteria.

PIPERACILLIN

X00B0D5O0E

Export Data
Search for Structure

Status:

US Approved Rx (2010)

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 2B

Penicillin-binding protein 1A

Conditions:

Intra-abdominal infections

Skin and skin structure infections

Female pelvic infections

Community-acquired pneumonia

Nosocomial pneumonia

Piperacillin is a semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic which exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. Piperacillin sodium salt is used in com...

bination with the β-lactamase inhibitor tazobactam sodium (ZOSYN®) for the treatment of patients with moderate to severe infections caused by susceptible bacteria.

CEFTIZOXIME ALAPIVOXIL

3MM3320LJN

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1983

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Conditions:

Meningitis caused by Haemophilus influenzae

Urinary tract infections

Lower respiratory tract infections

Pelvic inflammatory disease

Ceftizoxime is a semisynthetic cephalosporin antibiotic, which can be administered intravenously or intramuscularly. It was sold under brand name, cefizox, but was removed from the US Market in 2007. Cefizox was used to treat different infections, ...

such as lower respiratory tract infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenza; urinary tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. Also for treatment of gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae; pelvic inflammatory disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae; meningitis caused by Haemophilus influenza. In addition, some others infections. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae. Infections caused by aerobic gram ¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. The bactericidal action of ceftizoxime results from inhibition of the third and last stage of bacterial cell wall synthesis. Bacterial cell wall autolytic enzymes such as autolysins then mediate cell lysis; it is possible that ceftizoxime interferes with an autolysin inhibitor. Ceftizoxime is highly resistant to a broad spectrum of beta -lactamases (penicillinase and cephalosporinase), including Richmond types II, III, TEM, IV, produced by both aerobic and anaerobic gram - positive and gram - negative organisms and I.

Showing 1 - 10 of 12 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1